Barbara Hibner

Barbara brings 25 years of leadership experience in pharma and biotech to bear on new drug discovery. During her time at Bayer Pharmaceuticals she helped establish a new oncology department, and served as discovery co-project leader for sorafenib, later approved for kidney and liver cancers. Successive leadership positions at Chiron, Millennium Pharmaceuticals and Takeda consolidated a very broad-based expertise in advancing large and small molecule projects to and through clinical trials, including ixazomib for multiple myeloma. Barb is a co-founder and CSO for Decoy Therapeutics, applying peptide conjugate technologies to infectious disease and oncology medical needs.